Compare CVS Health Corp (CVS) vs Procter & Gamble Co (PG) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Procter & Gamble (PG) trades at $144.84, down 0.64% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.90. Fundamentals show robust profitability, including an 18.44% net income margin and 30.13% ROE, though valuation ratios like P/E of 22.12 and P/S of 4.08 are at premiums. Recent news highlights a WNBA partnership and a rejected mini-tender offer, while cash flow trends indicate stable operations.

PG offers a stable outlook with consistent dividend growth and efficient supply chain improvements, but faces risks from premium valuations and soft demand concerns. Analyst consensus is bullish with a $161.20 price target, though near-term upside may be limited by economic headwinds. Investment appeal lies in its defensive qualities and dividend reliability, balanced against competitive and margin pressures.